SARTORIUS STEDIM BIOTECH (56S1.DE) Fundamental Analysis & Valuation

FRA:56S1 • FR0013154002

169.05 EUR
-5.55 (-3.18%)
Last: Mar 6, 2026, 07:00 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Forecast Earnings Financials Ownership

This 56S1.DE fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

Fundamental Rating

4

Taking everything into account, 56S1 scores 4 out of 10 in our fundamental rating. 56S1 was compared to 22 industry peers in the Life Sciences Tools & Services industry. 56S1 has only an average score on both its financial health and profitability. 56S1 shows excellent growth, but is valued quite expensive already.


Dividend Valuation Growth Profitability Health

4

1. 56S1.DE Profitability Analysis

1.1 Basic Checks

  • In the past year 56S1 was profitable.
  • In the past year 56S1 had a positive cash flow from operations.
  • 56S1 had positive earnings in each of the past 5 years.
  • In the past 5 years 56S1 always reported a positive cash flow from operatings.
56S1.DE Yearly Net Income VS EBIT VS OCF VS FCF56S1.DE Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 200M 400M 600M 800M 1B

1.2 Ratios

  • 56S1 has a worse Return On Assets (3.33%) than 68.18% of its industry peers.
  • Looking at the Return On Equity, with a value of 6.50%, 56S1 is doing worse than 63.64% of the companies in the same industry.
  • 56S1 has a Return On Invested Capital (6.11%) which is comparable to the rest of the industry.
  • The Average Return On Invested Capital over the past 3 years for 56S1 is significantly below the industry average of 14.22%.
  • The 3 year average ROIC (5.23%) for 56S1 is below the current ROIC(6.11%), indicating increased profibility in the last year.
Industry RankSector Rank
ROA 3.33%
ROE 6.5%
ROIC 6.11%
ROA(3y)3.15%
ROA(5y)7.45%
ROE(3y)7.54%
ROE(5y)16.68%
ROIC(3y)5.23%
ROIC(5y)11.87%
56S1.DE Yearly ROA, ROE, ROIC56S1.DE Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 10 20 30

1.3 Margins

  • 56S1 has a Profit Margin (8.96%) which is in line with its industry peers.
  • 56S1's Profit Margin has declined in the last couple of years.
  • The Operating Margin of 56S1 (17.72%) is comparable to the rest of the industry.
  • In the last couple of years the Operating Margin of 56S1 has declined.
  • 56S1 has a Gross Margin of 45.33%. This is comparable to the rest of the industry: 56S1 outperforms 54.55% of its industry peers.
  • 56S1's Gross Margin has declined in the last couple of years.
Industry RankSector Rank
OM 17.72%
PM (TTM) 8.96%
GM 45.33%
OM growth 3Y-16.3%
OM growth 5Y-7.16%
PM growth 3Y-29.07%
PM growth 5Y-12.64%
GM growth 3Y-4.79%
GM growth 5Y-2.9%
56S1.DE Yearly Profit, Operating, Gross Margins56S1.DE Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 10 20 30 40 50

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

4

2. 56S1.DE Health Analysis

2.1 Basic Checks

  • With a Return on Invested Capital (ROIC) below the Cost of Capital (WACC), 56S1 is destroying value.
  • The number of shares outstanding for 56S1 remains at a similar level compared to 1 year ago.
  • 56S1 has more shares outstanding than it did 5 years ago.
  • Compared to 1 year ago, 56S1 has an improved debt to assets ratio.
56S1.DE Yearly Shares Outstanding56S1.DE Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 20M 40M 60M 80M
56S1.DE Yearly Total Debt VS Total Assets56S1.DE Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2B 4B 6B 8B

2.2 Solvency

  • An Altman-Z score of 3.85 indicates that 56S1 is not in any danger for bankruptcy at the moment.
  • The Altman-Z score of 56S1 (3.85) is better than 68.18% of its industry peers.
  • 56S1 has a debt to FCF ratio of 8.69. This is a slightly negative value and a sign of low solvency as 56S1 would need 8.69 years to pay back of all of its debts.
  • Looking at the Debt to FCF ratio, with a value of 8.69, 56S1 is in line with its industry, outperforming 40.91% of the companies in the same industry.
  • 56S1 has a Debt/Equity ratio of 0.49. This is a healthy value indicating a solid balance between debt and equity.
  • 56S1's Debt to Equity ratio of 0.49 is in line compared to the rest of the industry. 56S1 outperforms 54.55% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.49
Debt/FCF 8.69
Altman-Z 3.85
ROIC/WACC0.64
WACC9.59%
56S1.DE Yearly LT Debt VS Equity VS FCF56S1.DE Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 1B 2B 3B 4B

2.3 Liquidity

  • 56S1 has a Current Ratio of 1.02. This is a normal value and indicates that 56S1 is financially healthy and should not expect problems in meeting its short term obligations.
  • With a Current ratio value of 1.02, 56S1 is not doing good in the industry: 68.18% of the companies in the same industry are doing better.
  • A Quick Ratio of 0.53 indicates that 56S1 may have some problems paying its short term obligations.
  • 56S1's Quick ratio of 0.53 is on the low side compared to the rest of the industry. 56S1 is outperformed by 77.27% of its industry peers.
Industry RankSector Rank
Current Ratio 1.02
Quick Ratio 0.53
56S1.DE Yearly Current Assets VS Current Liabilites56S1.DE Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 500M 1B 1.5B

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

7

3. 56S1.DE Growth Analysis

3.1 Past

  • 56S1 shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 25.71%, which is quite impressive.
  • Measured over the past 5 years, 56S1 shows a small growth in Earnings Per Share. The EPS has been growing by 1.13% on average per year.
  • The Revenue has been growing slightly by 6.74% in the past year.
  • Measured over the past years, 56S1 shows a quite strong growth in Revenue. The Revenue has been growing by 9.21% on average per year.
EPS 1Y (TTM)25.71%
EPS 3Y-20.14%
EPS 5Y1.13%
EPS Q2Q%8.74%
Revenue 1Y (TTM)6.74%
Revenue growth 3Y-5.29%
Revenue growth 5Y9.21%
Sales Q2Q%2.78%

3.2 Future

  • The Earnings Per Share is expected to grow by 19.04% on average over the next years. This is quite good.
  • The Revenue is expected to grow by 11.26% on average over the next years. This is quite good.
EPS Next Y19.6%
EPS Next 2Y19.98%
EPS Next 3Y19.05%
EPS Next 5Y19.04%
Revenue Next Year7.44%
Revenue Next 2Y9.02%
Revenue Next 3Y9.46%
Revenue Next 5Y11.26%

3.3 Evolution

  • When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
  • The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
56S1.DE Yearly Revenue VS Estimates56S1.DE Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 2B 4B 6B
56S1.DE Yearly EPS VS Estimates56S1.DE Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 5 10

More info and screens

Find the best growth stocksShow best growing peers

0

4. 56S1.DE Valuation Analysis

4.1 Price/Earnings Ratio

  • Based on the Price/Earnings ratio of 38.42, the valuation of 56S1 can be described as expensive.
  • 77.27% of the companies in the same industry are cheaper than 56S1, based on the Price/Earnings ratio.
  • The average S&P500 Price/Earnings ratio is at 26.29. 56S1 is valued slightly more expensive when compared to this.
  • The Price/Forward Earnings ratio is 32.12, which means the current valuation is very expensive for 56S1.
  • Based on the Price/Forward Earnings ratio, 56S1 is valued a bit more expensive than 72.73% of the companies in the same industry.
  • Compared to an average S&P500 Price/Forward Earnings ratio of 24.60, 56S1 is valued a bit more expensive.
Industry RankSector Rank
PE 38.42
Fwd PE 32.12
56S1.DE Price Earnings VS Forward Price Earnings56S1.DE Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 10 20 30

4.2 Price Multiples

  • 68.18% of the companies in the same industry are cheaper than 56S1, based on the Enterprise Value to EBITDA ratio.
  • 56S1's Price/Free Cash Flow ratio is a bit more expensive when compared to the industry. 56S1 is more expensive than 63.64% of the companies in the same industry.
Industry RankSector Rank
P/FCF 55.03
EV/EBITDA 22.02
56S1.DE Per share data56S1.DE EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 10 20 30 40

4.3 Compensation for Growth

  • The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates 56S1 does not grow enough to justify the current Price/Earnings ratio.
  • 56S1's earnings are expected to grow with 19.05% in the coming years. This may justify a more expensive valuation.
PEG (NY)1.96
PEG (5Y)34.06
EPS Next 2Y19.98%
EPS Next 3Y19.05%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

4

5. 56S1.DE Dividend Analysis

5.1 Amount

  • With a yearly dividend of 0.41%, 56S1 is not a good candidate for dividend investing.
  • 56S1's Dividend Yield is comparable with the industry average which is at 0.45.
  • Compared to an average S&P500 Dividend Yield of 1.82, 56S1's dividend is way lower than the S&P500 average.
Industry RankSector Rank
Dividend Yield 0.41%

5.2 History

  • The dividend of 56S1 is nicely growing with an annual growth rate of 15.19%!
Dividend Growth(5Y)15.19%
Div Incr Years0
Div Non Decr Years1
56S1.DE Yearly Dividends per share56S1.DE Yearly Dividends per shareYearly Dividends per share 2022 2023 2024 2025 2026 0.5 1

5.3 Sustainability

  • 25.24% of the earnings are spent on dividend by 56S1. This is a low number and sustainable payout ratio.
  • The dividend of 56S1 is growing, but earnings are growing more, so the dividend growth is sustainable.
DP25.24%
EPS Next 2Y19.98%
EPS Next 3Y19.05%
56S1.DE Yearly Income VS Free CF VS Dividend56S1.DE Yearly Income VS Free CF VS DividendYearly Income VS Free CF VS Dividend 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 200M 400M 600M 800M
56S1.DE Dividend Payout.56S1.DE Dividend Payout, showing the Payout Ratio.56S1.DE Dividend Payout.PayoutRetained Earnings

More info and screens

Find the best dividend stocksShow peers with best dividend

56S1.DE Fundamentals: All Metrics, Ratios and Statistics

SARTORIUS STEDIM BIOTECH

FRA:56S1 (3/6/2026, 7:00:00 PM)

169.05

-5.55 (-3.18%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & Services
Earnings (Last)02-03
Earnings (Next)N/A
Inst Owners11.98%
Inst Owner ChangeN/A
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap16.45B
Revenue(TTM)2.97B
Net Income(TTM)265.80M
Analysts78.95
Price Target247.39 (46.34%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield 0.41%
Yearly Dividend0.69
Dividend Growth(5Y)15.19%
DP25.24%
Div Incr Years0
Div Non Decr Years1
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-7.48%
Min EPS beat(2)-12.72%
Max EPS beat(2)-2.24%
EPS beat(4)2
Avg EPS beat(4)4.36%
Min EPS beat(4)-12.72%
Max EPS beat(4)22.18%
EPS beat(8)3
Avg EPS beat(8)-1.28%
EPS beat(12)3
Avg EPS beat(12)-11.72%
EPS beat(16)3
Avg EPS beat(16)-14.26%
Revenue beat(2)0
Avg Revenue beat(2)-4.06%
Min Revenue beat(2)-4.17%
Max Revenue beat(2)-3.94%
Revenue beat(4)2
Avg Revenue beat(4)-1.07%
Min Revenue beat(4)-4.17%
Max Revenue beat(4)3.52%
Revenue beat(8)4
Avg Revenue beat(8)-1.65%
Revenue beat(12)5
Avg Revenue beat(12)-1.63%
Revenue beat(16)6
Avg Revenue beat(16)-1.17%
PT rev (1m)0.22%
PT rev (3m)2.79%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)-1.39%
EPS NY rev (3m)-1.16%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)-1.14%
Revenue NY rev (3m)-2.98%
Valuation
Industry RankSector Rank
PE 38.42
Fwd PE 32.12
P/S 5.54
P/FCF 55.03
P/OCF 23.77
P/B 4.02
P/tB N/A
EV/EBITDA 22.02
EPS(TTM)4.4
EY2.6%
EPS(NY)5.26
Fwd EY3.11%
FCF(TTM)3.07
FCFY1.82%
OCF(TTM)7.11
OCFY4.21%
SpS30.49
BVpS42.03
TBVpS-3.39
PEG (NY)1.96
PEG (5Y)34.06
Graham Number64.5
Profitability
Industry RankSector Rank
ROA 3.33%
ROE 6.5%
ROCE 8%
ROIC 6.11%
ROICexc 6.56%
ROICexgc 23.58%
OM 17.72%
PM (TTM) 8.96%
GM 45.33%
FCFM 10.08%
ROA(3y)3.15%
ROA(5y)7.45%
ROE(3y)7.54%
ROE(5y)16.68%
ROIC(3y)5.23%
ROIC(5y)11.87%
ROICexc(3y)5.56%
ROICexc(5y)12.62%
ROICexgc(3y)18.67%
ROICexgc(5y)31.48%
ROCE(3y)6.85%
ROCE(5y)15.55%
ROICexgc growth 3Y-18%
ROICexgc growth 5Y-10.32%
ROICexc growth 3Y-31.81%
ROICexc growth 5Y-17.24%
OM growth 3Y-16.3%
OM growth 5Y-7.16%
PM growth 3Y-29.07%
PM growth 5Y-12.64%
GM growth 3Y-4.79%
GM growth 5Y-2.9%
F-Score7
Asset Turnover0.37
Health
Industry RankSector Rank
Debt/Equity 0.49
Debt/FCF 8.69
Debt/EBITDA 2.39
Cap/Depr 123.61%
Cap/Sales 13.25%
Interest Coverage 3.42
Cash Conversion 82.03%
Profit Quality 112.49%
Current Ratio 1.02
Quick Ratio 0.53
Altman-Z 3.85
F-Score7
WACC9.59%
ROIC/WACC0.64
Cap/Depr(3y)145.19%
Cap/Depr(5y)180.27%
Cap/Sales(3y)14.18%
Cap/Sales(5y)13.22%
Profit Quality(3y)157.37%
Profit Quality(5y)116.81%
High Growth Momentum
Growth
EPS 1Y (TTM)25.71%
EPS 3Y-20.14%
EPS 5Y1.13%
EPS Q2Q%8.74%
EPS Next Y19.6%
EPS Next 2Y19.98%
EPS Next 3Y19.05%
EPS Next 5Y19.04%
Revenue 1Y (TTM)6.74%
Revenue growth 3Y-5.29%
Revenue growth 5Y9.21%
Sales Q2Q%2.78%
Revenue Next Year7.44%
Revenue Next 2Y9.02%
Revenue Next 3Y9.46%
Revenue Next 5Y11.26%
EBIT growth 1Y41.93%
EBIT growth 3Y-20.72%
EBIT growth 5Y1.39%
EBIT Next Year55.74%
EBIT Next 3Y26.51%
EBIT Next 5Y22.89%
FCF growth 1Y-37.09%
FCF growth 3Y18.06%
FCF growth 5Y3.02%
OCF growth 1Y-15.08%
OCF growth 3Y4.17%
OCF growth 5Y10.67%

SARTORIUS STEDIM BIOTECH / 56S1.DE FAQ

What is the ChartMill fundamental rating of SARTORIUS STEDIM BIOTECH (56S1.DE) stock?

ChartMill assigns a fundamental rating of 4 / 10 to 56S1.DE.


Can you provide the valuation status for SARTORIUS STEDIM BIOTECH?

ChartMill assigns a valuation rating of 0 / 10 to SARTORIUS STEDIM BIOTECH (56S1.DE). This can be considered as Overvalued.


How profitable is SARTORIUS STEDIM BIOTECH (56S1.DE) stock?

SARTORIUS STEDIM BIOTECH (56S1.DE) has a profitability rating of 4 / 10.


Can you provide the PE and PB ratios for 56S1 stock?

The Price/Earnings (PE) ratio for SARTORIUS STEDIM BIOTECH (56S1.DE) is 38.42 and the Price/Book (PB) ratio is 4.02.


What is the earnings growth outlook for SARTORIUS STEDIM BIOTECH?

The Earnings per Share (EPS) of SARTORIUS STEDIM BIOTECH (56S1.DE) is expected to grow by 19.6% in the next year.